<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143078">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106884</url>
  </required_header>
  <id_info>
    <org_study_id>s56122</org_study_id>
    <secondary_id>2013-004101-75</secondary_id>
    <secondary_id>AX-CL-PANC-PI-003568</secondary_id>
    <nct_id>NCT02106884</nct_id>
  </id_info>
  <brief_title>Quality of Life Study in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel</brief_title>
  <acronym>QOLINPAC</acronym>
  <official_title>Randomized Crossover Trial to Assess the Effects and Quality of Life in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel: QOLINPAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a quality of life study done in the context of a randomized trial in pancreatic
      cancer. Patients with locally advanced or metastatic pancreatic adenocarcinoma receive
      either the combination of nab-paclitaxel gemcitabine or the existing standard gemcitabine
      alone treatment.The combination regimen of nab-paclitaxel and gemcitabine administered in
      patients with locally advanced or metastatic pancreatic cancer in a first line setting
      showed improved efficacy with acceptable toxicity. The current study design allows patients
      in standard treatment to receive the combination treatment at tumour progression.

      The proposed study will explore the impact of treatment on the quality of life and compare
      the times to definitive deterioration of the quality of life scores using the validated
      EORTC QLQ-C30. Efficacy and safety secondary endpoints are to be reported in a descriptive
      manner.

      Molecular studies will be performed on blood and tissue samples.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Deterioration free rate of quality of life (QOL) scores at three months</measure>
    <time_frame>upto 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>QOL questionnaires will be applied to patients every 4 weeks for a maximum of 12 months. The primary endpoint will be analysed at the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile (NCI-CTCAE v. 4.0)</measure>
    <time_frame>Weekly upto 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Descriptive safety, incidence of treatment-emergent toxicities in both arms and incidence of dose modifications, interruptions and discontinuations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response and duration of response</measure>
    <time_frame>q8 weeks upto 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response and disease control rates - response evaluation will be performed every 8 weeks according to RECIST criteria (CT/ MRI scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>q8 weeks upto 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>From date of randomization until the date of death from any cause assessed up to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum CA 19-9 and CEA and composite index CA19-9xCEA</measure>
    <time_frame>Every 8 weeks upto 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of the levels of carbohydrate antigen 19 9 (CA19 9) on treatment (q 8 weeks) and composite index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarker and hypoxia studies on blood products and tumour tissues with possible correlations with efficacy outcomes</measure>
    <time_frame>Baseline for tissue; 3 timepoints for blood collection(baseline, Week 9, Progression - maximum 12 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biomarkers that can be related with benefit to nab-paclitaxel:
Potential SNPs
Circulating DNA
Circulating micro-RNA
Selected cytokines (ELISA)
hENT1, SPARC, dCK and S100A2 expression (immunohistochemistry/qPCR)
Hypoxia studies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abraxane (nab-paclitaxel) -  IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine - IV - 1000 mg/m2 - 3xq4wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane (nab-paclitaxel)</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Abraxane, nab-paclitaxel, EU/1/07/428/001, L01CD01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (+ optional for TR) must be given according to ICH/GCP and
             national/local regulations.

          -  Patient is at least 18 years of age .

          -  Unresectable locally advanced or metastatic pancreatic cancer.

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas. Islet cell
             neoplasms are excluded.

          -  Evaluable or measurable disease, not in a previously irradiated area.

          -  Life expectancy of at least 12 weeks.

          -  WHO ECOG performance status â‰¤ 2

          -  Adequate organ function.

          -  Adequate bone marrow, hepatic and renal function:

        Acceptable coagulation (prothrombin time and partial thromboplastin time within +/- 15% of
        normal limits).

          -  No clinically significant abnormalities in urinalysis.

          -  Effective contraception for both male and female patients if applicable. Women of
             childbearing potential must have negative blood pregnancy test at screening visit.

        Exclusion criteria:

          -  Prior chemotherapy, radiotherapy, surgery or other investigational therapy for the
             treatment for metastatic disease. Adjuvant treatment with gemcitabine or 5-FU is
             allowed provided at least 6 months have elapsed since completion of the last dose.

          -  Major surgery within 4 weeks of the start of the study.

          -  Irradiation within 3 weeks prior to study entry.

          -  Brain metastasis (known or suspected).

          -  Serious medical risk factors involving any of the major organ systems, including high
             cardiovascular risk including coronary stenting or myocardial infarction in the last
             year and psychiatric disorders.

          -  Historical or active infection with HIV, hepatitis B or C.

          -  History of connective tissue disorders (eg. lupus, scleroderma, arteritis nodosa,
             etc).

          -  History of interstitial lung disease.

          -  History of peripheral artery disease.

          -  Previous (within 5 years) or concurrent malignancies at other sites with the
             exception of surgically cured or adequately treated carcinoma in-situ of the cervix
             and basal cell carcinoma of the skin.

          -  Known allergy or any other adverse reaction to any of the drugs or to any related
             compound.

          -  Use of Coumadin.

          -  Organ allografts requiring immunosuppressive therapy.

          -  Pregnancy or breast-feeding.

          -  Medical, social or psychological condition which, in the opinion of the investigator,
             would not permit the patient to complete the study or sign meaningful informed
             consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Cutsem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Van Cutsem, MD</last_name>
    <phone>016/344218</phone>
    <email>eric.vancutsem@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koen Hendrickx, MD</last_name>
      <email>koen.hendrickx@olvz-aalst.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joris Arts, MD</last_name>
      <email>joris.arts@stlucas.be</email>
    </contact>
    <investigator>
      <last_name>Joris Arts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Borbath, MD</last_name>
      <email>ivan.borbath@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Ivan Borbath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brahim Ramdani, MD</last_name>
      <email>brahim.ramdani@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Brahim Ramdani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Peeters, MD</last_name>
      <email>marc.peeters@uza.be</email>
    </contact>
    <investigator>
      <last_name>Marc Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>StÃ©phanie Laurent, MD</last_name>
      <email>stephanielaurent@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Stephanie Laurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Van Cutsem, MD</last_name>
      <phone>016/344218</phone>
      <email>eric.vancutsem@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Eric Van Cutsem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Delhougne, MD</last_name>
      <email>bernard.delhougne@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Bernard Delhougne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC St Joseph</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ghislain Houbiers, MD</last_name>
      <email>ghislain.houbiers@chc.be</email>
    </contact>
    <investigator>
      <last_name>Ghislain Houbiers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Van Daele, MD</last_name>
      <email>Daniel.VanDaele@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Daniel Van Daele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Ferrante, MD</last_name>
      <email>michel.ferrante@emmaus.be</email>
    </contact>
    <investigator>
      <last_name>Michel Ferrante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique St Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Charles Goeminne, MD</last_name>
      <email>jeancharlesgoeminne@cmsenamur.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Charles Goeminne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jos Janssens, MD</last_name>
      <email>jos.janssens@azturnhout.be</email>
    </contact>
    <investigator>
      <last_name>Jos Janssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
